// App-Quantinova.ai

3563 : Intensified Chemotherapy Regimen for Very High Risk Childhood B-Precursor Acute Lymphoblastic Leukemia (B-ALL): Results From Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 0501

Researchers

Presenter

  • Lynda M. Vrooman

Principal Investigators

  • Kristen E. Stevenson

  • Marian Harris

  • Donna S. Neuberg

  • Stephen E. Sallan

  • Lewis B. Silverman

Medical Centers

  • Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

  • Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Childrens Hospital, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • White Blood Cell

  • T-cell receptor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Doxorubicin

  • Cytarabine liposomal

  • Etoposide

  • Etoposide phosphate

  • 6-mercaptopurine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved